Allarity Therapeutics, Inc. ALLR
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -9.47%
- 1 year
- -32.57%
- Open
- 0.8735
- Prev close
- 0.8704
- Mkt cap
- 15.56M
- Vol
- 166.74K
- Avg vol
- 111.70K
- EPS
- -0.79
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.8735
- High
- 1.03
- Forward P/E
- -0.02
- Beta
- 0.29
- Short ratio
- 0.30
- Inst. own
- 2.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 5, 2024
- 50-d avg
- 1.30
- 200-d avg
- 28.72
- 1y target
- 0.00
5D chart
Signals (70)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 3:55 PM | 5 hours ago |
| MACD: Sell Signal | Nov 2, 3:55 PM | 5 hours ago |
| MACD: Buy Signal | Nov 2, 3:40 PM | 6 hours ago |
| MACD: Sell Signal | Nov 2, 3:20 PM | 6 hours ago |
| SMA: Bullish | Nov 2, 2:55 PM | 6 hours ago |
| SMA: Bearish | Nov 2, 2:40 PM | 7 hours ago |
| SMA: Bullish | Nov 2, 2:35 PM | 7 hours ago |
| SMA: Bearish | Nov 2, 2:30 PM | 7 hours ago |
| RSI: Overbought | Nov 2, 2:00 PM | 7 hours ago |
| SMA: Bullish | Nov 2, 12:30 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 11:55 AM | 9 hours ago |
| SMA: Bullish | Nov 2, 9:40 AM | 12 hours ago |
| SMA: Bearish | Oct 30, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:15 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 11:20 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:05 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:50 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:20 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:10 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:55 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:10 PM | 6 days ago |
News
-
13 hours ago benzinga.com
Allarity Therapeutics Settles $4.9M Novartis Liability For $1M Payment
On October 28, 2026, Allarity Therapeutics, Inc. (the "Company") entered into a Settlement and Release Agreement (the "Settlement Agreement") with Novartis Pharma AG ("Novartis") relating to an
-
3 days ago benzinga.com
Allarity Therapeutics Receives First Contract For Its Development, Validation And Related Laboratory Services From Undisclosed European Biotech Firm
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT
3 days ago globenewswire.com
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
- Agreement complements revenue from standard gene expression and DRP® services - Development and validation services will support a European biotechnology company's precision oncology predictive…
3 weeks ago zacks.com
Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for Allarity Therapeutics, Inc. (ALLR), indicating that the stock has found support. This, combined with an upward trend in…
4 weeks ago defenseworld.net
Critical Review: Evogene (NASDAQ:EVGN) vs. Allarity Therapeutics (NASDAQ:ALLR)
Evogene (NASDAQ: EVGN - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two…
1 month ago defenseworld.net
Allarity Therapeutics (NASDAQ:ALLR) versus Autolus Therapeutics (NASDAQ:AUTL) Head to Head Analysis
Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) and Autolus Therapeutics (NASDAQ: AUTL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will…
-
1 month ago benzinga.com
Allarity Therapeutics Highlights DRP Technology, Patent And Lab Advances To Support Stenoparib Development And Partnerships
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT
1 month ago globenewswire.com
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical Development
- Recently awarded patents have solidified Allarity's strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SPRINGS, Fla., September 30, 2026 – Allarity Therapeutics,…
-
1 month ago benzinga.com
Allarity Therapeutics Expands Capabilities Of Its In-House Medical Laboratory To Include Proteomics And Cell Line Research
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib- New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable…
1 month ago globenewswire.com
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity's research capabilities to enable…
1 month ago defenseworld.net
Financial Contrast: Xenetic Biosciences (NASDAQ:XBIO) & Allarity Therapeutics (NASDAQ:ALLR)
Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
1 month ago benzinga.com
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
1 month ago benzinga.com
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
-
1 month ago benzinga.com
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $10.25 to $11.
1 month ago globenewswire.com
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib…
1 month ago globenewswire.com
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing…
-
2 months ago benzinga.com
Allarity Therapeutics Q2 EPS $(0.21) Beats $(0.25) Estimate
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.25) by 16 percent. This is a 40 percent decrease over losses of…
2 months ago globenewswire.com
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP ® companion…
3 months ago zacks.com
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
-
3 months ago benzinga.com
Allarity Therapeutics Secures CLIA For In-House Lab
Allarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory environment The FDA requires that biomarker testing to select patients for registration trials must…
3 months ago globenewswire.com
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
Allarity Therapeutics is now poised to run its DRP ® testing in-house in a CLIA-certified laboratory environment The FDA requires that biomarker testing to select patients for registration trials…
3 months ago zacks.com
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sector so far this year.
-
4 months ago benzinga.com
Allarity Therapeutics Receives U.S. Patent And Trademark Office Patent For Its Drug Response Predictor Companion Diagnostic
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and…
4 months ago globenewswire.com
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the…
4 months ago seekingalpha.com
Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript
Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ:ALLR) stock…
4 months ago zacks.com
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (ATHE) have performed compared to their sector so far this year.
-
4 months ago benzinga.com
Allarity Therapeutics To Present A Trial-In-Progress Poster At The ESMO Gynaecological Cancers Congress, June 17–19
The poster outlines the scientific background, study design, and clinical rationale for the Company's ongoing Phase 2 trial evaluating stenoparib in patients with advanced platinum-resistant or…
4 months ago globenewswire.com
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
Principal Investigator Kathleen N. Moore, M.D.
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
4 months ago benzinga.com
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.75 to $10.25.
5 months ago zacks.com
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their sector so far this year.
-
5 months ago benzinga.com
Allarity Therapeutics Q1 EPS $(0.17) Beats $(0.22) Estimate, Sales $25.000K
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 32 percent increase over losses of…
5 months ago globenewswire.com
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer- Allarity has received a Notice of Allowance for new…
-
6 months ago benzinga.com
Allarity Therapeutics Says API Manufacturing Campaign For Stenoparib Is Progressing In Line With Planned Timeline For Completion No Later Than Q3 Of 2026 At CDMO
Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancer Supports accelerating stenoparib toward FDA…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
1 year ago benzinga.com
Crude Oil Down 2%; US Durable Goods Orders Decline In July
Crude Oil Down 2%; US Durable Goods Orders Decline In July
1 year ago benzinga.com
US Stocks Mixed; American Woodmark Posts Downbeat Sales
US Stocks Mixed; American Woodmark Posts Downbeat Sales
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
1 year ago benzinga.com
US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert
U.S. stock futures were swinging between gains and losses on Tuesday after a mixed session on Monday. Futures of major benchmark indices were mixed in premarket trading. President Donald Trump‘s…
1 year ago benzinga.com
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
2 years ago benzinga.com
Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket
Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session